Your browser doesn't support javascript.
loading
Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma.
Shteinman, Eva R; Vergara, Ismael A; Rawson, Robert V; Lo, Serigne N; Maeda, Naoyuki; Koyama, Kumiko; da Silva, Inês Pires; Long, Georgina V; Scolyer, Richard A; Wilmott, James S; Menzies, Alexander M.
Affiliation
  • Shteinman ER; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
  • Vergara IA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
  • Rawson RV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.
  • Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Maeda N; Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Koyama K; Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • da Silva IP; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
  • Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Ho
  • Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: alexander.menzies@sydney.edu.au.
Pathology ; 55(5): 629-636, 2023 Aug.
Article in En | MEDLINE | ID: mdl-37286471
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pathology Year: 2023 Type: Article Affiliation country: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pathology Year: 2023 Type: Article Affiliation country: Australia